Istvan Molnar
Chief Medical Officer
Oncologist and Hematologist
Fusion Pharmaceuticals
Canada
Biography
Dr. Molnar is a medical oncologist and hematologist who practiced internal medicine, hematology and oncology both in private practice and in academia in the United States before starting his industry career. Before joining Fusion, he was Vice President of Development at Merrimack Pharmaceuticals where he worked in early, mid and late stage development of the liposomal chemotherapeutic portfolio of Merrimack. During his tenure at Merrimack, he made major contribution to the successful marketing approval of Onivyde in pancreatic cancer. Previous to Merrimack, Dr. Molnar spent 7 years at Bayer Pharmaceuticals with increasing responsibilities. While at Bayer, he worked in global medical affairs and subsequently in Global Clinical Development on different projects that included Xofigo, Nexavar, Campath and Zevalin among others. He led the clinical team in the successful marketing approval for Nexavar in differentiated thyroid cancer. Prior to joining Bayer, he was on faculty at Wake Forest University in North Carolina where he focused his clinical practice on myelodysplastic syndrome and acute leukemia. Dr. Molnar received his medical degree from Semmelweis University in Budapest, Hungary.
Research Interest
Oncologist , Hematologist and Internal Medicine
